News Releases

DateTitle 
07/12/20
– In a rare dual-review process, two independent advisory committees to the Australian Minister for Health recommend reimbursement based on a favorable clinical and cost-effectiveness comparison – STAINES-UPON-THAMES, United Kingdom and LAKEWOOD, Colo. USA – July 13, 2020 –  Mallinckrodt plc
Printer Friendly Version
07/09/20
STAINES-UPON-THAMES, United Kingdom , July 9, 2020 /PRNewswire/ -- Mallinckrodt plc  (NYSE: MNK), a global biopharmaceutical company, announced today that it will report second quarter 2020 earnings results for the period ended June 26, 2020 on Tuesday, Aug.
Printer Friendly Version
07/07/20
- Advisory committee meeting scheduled for July 15, 2020 - STAINES-UPON-THAMES, United Kingdom , July 7, 2020 /PRNewswire/ --  Mallinckrodt plc  (NYSE: MNK), a global biopharmaceutical company, today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U.S.
Printer Friendly Version
06/17/20
STAINES-UPON-THAMES, United Kingdom , June 17, 2020 /PRNewswire/ --  Mallinckrodt plc  (NYSE: MNK), a global biopharmaceutical company, will present on Tuesday, June 23, 2020 at the BMO Prescriptions for Success Healthcare Conference . Mark Trudeau , President and Chief Executive Officer, and Bryan
Printer Friendly Version
06/15/20
-- Company remains committed to opioid settlement in principle but says allowing District Court ruling to stand could adversely impact settlement completion -   --Appeals Court sets expedited briefing and oral argument schedule--   -- Company continues to explore all options to address its
Printer Friendly Version
06/15/20
-- Phase 3 Clinical Trial Selected Among "Top Five Abstracts" --   -- Additional Abstracts on Health Economics and Outcomes Research and Other Data Accepted as Poster Presentations -- STAINES-UPON-THAMES, United Kingdom , June 15, 2020 /PRNewswire/ --  Mallinckrodt plc  (NYSE: MNK), a global
Printer Friendly Version
06/11/20
- U.K. medical chart study showed an association between patients treated with terlipressin and an improvement in kidney function in 73 percent of hospitalized adult patients with HRS-1 - STAINES-UPON-THAMES, United Kingdom , June 11, 2020 /PRNewswire/ --  Mallinckrodt plc  (NYSE: MNK), a global
Printer Friendly Version
06/09/20
- StrataGraft® Skin Tissue is in Development as Potential New Treatment Option for Patients with Deep Partial-thickness Thermal Burns - STAINES-UPON-THAMES, United Kingdom , June 9, 2020 /PRNewswire/ --  Mallinckrodt plc  (NYSE: MNK), a global biopharmaceutical company, today announced that
Printer Friendly Version
06/01/20
-- Company believes District Court decision misinterprets federal law and fails to address important legal requirements of the Administrative Procedure Act --   -- Company will immediately appeal to the U.S. Court of Appeals for the D.C. Circuit to overturn District Court decision and block CMS
Printer Friendly Version
05/05/20
STAINES-UPON-THAMES, United Kingdom , May 5, 2020 /PRNewswire/ -- First quarter net sales of $665.8 million , with diluted loss per share of $0.60 , with results impacted in part by competitive and payer pressures in certain products and a decline in demand due to COVID-19 Adjusted diluted earnings
Printer Friendly Version
05/04/20
- Company ends Phase 4 observational registry early as data achieved statistical significance for non-inferiority in premature neonates compared to term and near-term neonates at planned interim analysis - STAINES-UPON-THAMES, United Kingdom , May 4, 2020 /PRNewswire/ --  Mallinckrodt plc  (NYSE:
Printer Friendly Version
04/30/20
- More than 170 U.S. hospitals have reported using INOmax® (nitric oxide) gas, for inhalation, to treat COVID-19 lung complications - STAINES-UPON-THAMES, United Kingdom , April 30, 2020 /PRNewswire/ --  Mallinckrodt plc  (NYSE: MNK), a global biopharmaceutical company, announced today that it is
Printer Friendly Version
04/22/20
- Terlipressin would be the first FDA-approved treatment option in the United States for adult patients with HRS-1, a life-threatening condition, if approved - STAINES-UPON-THAMES, United Kingdom , April 22, 2020 /PRNewswire/ -- Mallinckrodt plc  (NYSE: MNK), a global biopharmaceutical company,
Printer Friendly Version
04/16/20
STAINES-UPON-THAMES, United Kingdom , April 16, 2020 /PRNewswire/ -- Mallinckrodt plc  (NYSE: MNK), a global biopharmaceutical company, announced today that it will report first quarter 2020 earnings results for the period ended March 27, 2020 on Tuesday, May 5, 2020 .  A conference call for
Printer Friendly Version
04/15/20
-- The two-part multicenter study of 259 enrolled subjects showed >60 percent of patients achieved low disease activity (LDA) at week 12 with open-label therapy, an effect that was maintained in a proportion of patients with 12 additional weeks of treatment in the double-blind phase --
Printer Friendly Version
04/06/20
- Application is Supported by Data from Pivotal Phase 3 Study for the Treatment of Deep Partial-Thickness Thermal Burns - - StrataGraft Skin Tissue Could be a Potential New Treatment Option for Deep Partial-Thickness Thermal Burns, if Approved - STAINES-UPON-THAMES, United Kingdom , April 6, 2020
Printer Friendly Version
04/01/20
-- Study to investigate antiviral activity and improvement in oxygenation and pulmonary arterial pressure in patients suffering from COVID-19 -- STAINES-UPON-THAMES, United Kingdom and GARDEN GROVE, Calif. , April 1, 2020 /PRNewswire/ -- Mallinckrodt plc  (NYSE: MNK), a global biopharmaceutical
Printer Friendly Version
03/20/20
Mar. 20, 2020-- Mallinckrodt Pharmaceuticals , a global biopharmaceutical company, has been monitoring the development of the novel coronavirus (COVID-19) outbreak using our resources in conjunction with the appropriate global health and security agencies.
Printer Friendly Version
03/17/20
- Terlipressin would be the first FDA-approved treatment option in the United States for adult patients with HRS-1, a life-threatening condition, if approved - STAINES-UPON-THAMES, United Kingdom , March 17, 2020 /PRNewswire/ --  Mallinckrodt plc  (NYSE: MNK), a global biopharmaceutical company,
Printer Friendly Version
03/16/20
-- Court allows CMS to change Medicaid rebate calculations for Acthar® Gel resulting in full retroactive payments -- -- Retroactive liability of approximately $650 million and prospective loss of Acthar Gel Medicaid net sales of roughly $90 million to $100 million in net sales annualized -- --
Printer Friendly Version
03/12/20
STAINES-UPON-THAMES, United Kingdom , March 12, 2020 /PRNewswire/ --  Mallinckrodt plc  (NYSE: MNK), a global biopharmaceutical company, today commented that it is currently evaluating the limited published evidence suggesting a potential role for inhaled nitric oxide ("iNO") as a supportive
Printer Friendly Version
03/11/20
New York State Attorney General Supports Company's Proposed Global Opioid Settlement; Joining 47 Other State and U.S. Territory Attorneys General STAINES-UPON-THAMES, United Kingdom, March 11, 2020 /PRNewswire/ --  Mallinckrodt plc (NYSE: MNK) ("Mallinckrodt" or the "Company") today announced that
Printer Friendly Version
03/05/20
-- In a prospective, open-label study of 19 adult patients with biopsy-proven lgAN at high risk of progression to end-stage renal disease, treatment with Acthar Gel demonstrated a reduction in proteinuria, an effect which was sustained at 12 months -- STAINES-UPON-THAMES, United Kingdom , March 5,
Printer Friendly Version
03/04/20
-- Retrospective chart review assessing Acthar Gel treatment utilization and patterns in 92 patients suggests improvement in symptoms across three disease states in a real-world setting -- STAINES-UPON-THAMES, United Kingdom , March 4, 2020 /PRNewswire/ --  Mallinckrodt plc  (NYSE: MNK), a global
Printer Friendly Version
03/02/20
- Terlipressin would be the first FDA-approved treatment option in the United States for patients with HRS-1 if approved - STAINES-UPON-THAMES, United Kingdom , March 2, 2020 /PRNewswire/ --  Mallinckrodt plc  (NYSE: MNK), a global biopharmaceutical company, today announced it initiated the rolling
Printer Friendly Version
02/27/20
-- Data highlights include prospective observational registry top-line results and interim baseline patient characteristics at 50 percent enrollment from randomized, double-blind, placebo-controlled OPTIONS study of Acthar Gel in MS relapse -- STAINES-UPON-THAMES, United Kingdom , Feb.
Printer Friendly Version
02/25/20
- Fourth quarter net sales of $804.9 million and 2019 net sales of $3.163 billion, with strong performance across hospital products and the Specialty Generics segment, offset by declines in Acthar® Gel - Diluted loss per share of $13.76 in the fourth quarter and $11.88 in fiscal 2019; adjusted
Printer Friendly Version
02/25/20
Agreement in Principle with Court-Appointed Plaintiffs' Executive Committee Representing the Interests of Thousands of Plaintiffs in the Opioid Multidistrict Litigation; Supported by a Broad-Based Group of 47 State and U.S. Territory Attorneys General Settlement Terms Include Structured Payments of
Printer Friendly Version
02/14/20
STAINES-UPON-THAMES, United Kingdom , Feb. 14, 2020 /PRNewswire/ --  Mallinckrodt plc  (NYSE: MNK), a global biopharmaceutical company, announced today that it will report fourth quarter and fiscal 2019 earnings results for the period ending Dec. 27, 2019 on Tuesday, Feb.
Printer Friendly Version
01/30/20
-- Company scores 100 percent on Human Rights Campaign Foundation's 18th annual Corporate Equality Index on LGBTQ Workplace Equality for Fourth Year in a Row-- STAINES-UPON-THAMES, United Kingdom , Jan. 30, 2020 /PRNewswire/ --  Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company,
Printer Friendly Version